Millennium Management LLC Sells 214,419 Shares of Genelux Co. (NASDAQ:GNLX)

Millennium Management LLC decreased its position in Genelux Co. (NASDAQ:GNLX - Free Report) by 58.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 150,510 shares of the company's stock after selling 214,419 shares during the period. Millennium Management LLC owned about 0.44% of Genelux worth $355,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GNLX. Marshall Wace LLP boosted its stake in shares of Genelux by 51.4% during the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock valued at $368,000 after buying an additional 52,958 shares during the period. LPL Financial LLC lifted its stake in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock valued at $222,000 after purchasing an additional 39,516 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Genelux in the 4th quarter valued at $51,000. Raymond James Financial Inc. acquired a new stake in shares of Genelux in the 4th quarter valued at $41,000. Finally, Virtu Financial LLC acquired a new stake in shares of Genelux in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 37.33% of the company's stock.

Wall Street Analysts Forecast Growth

GNLX has been the subject of several analyst reports. Benchmark reduced their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen raised shares of Genelux from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Genelux in a research note on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $17.75.

Genelux Trading Up 15.5%

GNLX traded up $0.41 during trading on Friday, hitting $3.06. The stock had a trading volume of 579,660 shares, compared to its average volume of 190,305. The firm has a market cap of $115.47 million, a PE ratio of -3.22 and a beta of -0.49. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $5.89. The company has a 50 day simple moving average of $2.59 and a 200-day simple moving average of $3.07.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. As a group, sell-side analysts anticipate that Genelux Co. will post -0.88 earnings per share for the current fiscal year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.